PHP
ATXS

Parkman Healthcare Partners’s Astria Therapeutics ATXS Stock Holding History

Parkman Healthcare Partners’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-24,250
Closed -$901K – 86
2020
Q3 		$901K Sell
24,250
-1,662
-6% -$65.9K 0.24% 72
2020
Q2 		$1M Hold
25,912
– – 0.28% 68
2020
Q1 		$645K Buy
+25,912
New +$803K 0.3% 61

Other funds holding ATXS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Parkman Healthcare Partners's ATXS Position: Q4 2020 in Review

Parkman Healthcare Partners sold out of Astria Therapeutics (ATXS) in Q4 2020, closing a stake of 24,250 shares — an estimated $901K sold.

Parkman Healthcare Partners first reported a position in ATXS in Q1 2020 and held it in 3 quarters. The position peaked at $1M in Q2 2020. 62 funds tracked by Wall St. Rank hold ATXS as of Q4 2020.

  • Parkman Healthcare Partners reported no remaining Astria Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Parkman Healthcare Partners sold 24,250 Astria Therapeutics shares in Q4 2020, an estimated $901K.
  • Parkman Healthcare Partners first reported a position in Astria Therapeutics in Q1 2020 and held it in 3 quarters.
  • Parkman Healthcare Partners's Astria Therapeutics position peaked at $1M in Q2 2020.
  • 62 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2020.

Based on Parkman Healthcare Partners's 13F filing for Q4 2020, filed 12 Feb 2021.